TCF25

Across TCGA pan-cancer cohorts, TCF25 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TCF25 data layer compared with 19 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in pheochromocytoma and paraganglioma (PCPG), where higher TCF25 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TCF25 expression acts as an unfavorable survival marker.

PCPG, LIHC, and MESO are the cancer types where TCF25 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PCPG	OS	Median	All	0.010	0.946	<.001	12	view →
LIHC	DFS	Median	All	0.119	0.557	.001	12	view →
MESO	DFS	Median	III,IV	0.078	0.376	.012	9	view →
STAD	OS	Median	All	0.170	0.567	.033	6	view →
ESCA	OS	Median	II,III,IV	0.321	0.685	.035	6	view →
SKCM	DFS	Median	II,III,IV	0.058	0.708	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TCF25–PCPG (OS)

Open the PCPG breakdown →